Tyverb (lapatinib) is an oral antineoplastic agent that may provide women with an alternative option when other breast cancer treatments have failed.

Tyverb is indicated in combination with capecitabine for advanced or metastatic breast cancer in patients whose tumours overexpress ErbB2 (HER2). Patients should have progressive disease following prior therapy that included anthracyclines and taxanes and trastuzumab in the metastatic setting.

Lapatinib has a 'conditional licence' which is valid for 1 year and requires GSK to provide further trial data. A conditional licence is granted when a drug fulfils an unmet medical need and the benefit to public health outweighs the risk that additional data are still required.

View Tyverb drug record

Further information: GlaxoSmithKline

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases